153 related articles for article (PubMed ID: 29703727)
1. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
Sallman DA; Brayer J; Sagatys EM; Lonez C; Breman E; Agaugué S; Verma B; Gilham DE; Lehmann FF; Davila ML
Haematologica; 2018 Sep; 103(9):e424-e426. PubMed ID: 29703727
[No Abstract] [Full Text] [Related]
2. CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart.
Vagnozzi RJ; Johansen AKZ; Molkentin JD
Mol Ther; 2019 Nov; 27(11):1869-1871. PubMed ID: 31585799
[No Abstract] [Full Text] [Related]
3. Chimeric antigen receptor T-cell therapy in childhood acute myeloid leukemia: how far are we from a clinical application?
Naik S; Velasquez MP; Gottschalk S
Haematologica; 2024 Jun; 109(6):1656-1667. PubMed ID: 38832421
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Cummins KD; Gill S
Haematologica; 2019 Jul; 104(7):1302-1308. PubMed ID: 31221785
[No Abstract] [Full Text] [Related]
5. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Hegde M; Joseph SK; Pashankar F; DeRenzo C; Sanber K; Navai S; Byrd TT; Hicks J; Xu ML; Gerken C; Kalra M; Robertson C; Zhang H; Shree A; Mehta B; Dakhova O; Salsman VS; Grilley B; Gee A; Dotti G; Heslop HE; Brenner MK; Wels WS; Gottschalk S; Ahmed N
Nat Commun; 2020 Jul; 11(1):3549. PubMed ID: 32669548
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic challenges on the horizon of chimeric antigen receptor-T.
Benincasa G; Strozziero MG; Di Pastena MA; Criscuolo C; Cetani G; Trama U; Napoli C
Cytotherapy; 2024 May; 26(5):411-412. PubMed ID: 38466261
[No Abstract] [Full Text] [Related]
7. Structural surfaceomics reveals an AML-specific conformation of integrin β
Mandal K; Wicaksono G; Yu C; Adams JJ; Hoopmann MR; Temple WC; Izgutdina A; Escobar BP; Gorelik M; Ihling CH; Nix MA; Naik A; Xie WH; Hübner J; Rollins LA; Reid SM; Ramos E; Kasap C; Steri V; Serrano JAC; Salangsang F; Phojanakong P; McMillan M; Gavallos V; Leavitt AD; Logan AC; Rooney CM; Eyquem J; Sinz A; Huang BJ; Stieglitz E; Smith CC; Moritz RL; Sidhu SS; Huang L; Wiita AP
Nat Cancer; 2023 Nov; 4(11):1592-1609. PubMed ID: 37904046
[TBL] [Abstract][Full Text] [Related]
8. Lowering mTORC1 Drives CAR T-Cells Home in Acute Myeloid Leukemia.
Maiti A; Daver NG
Clin Cancer Res; 2021 Nov; 27(21):5739-5741. PubMed ID: 34470774
[TBL] [Abstract][Full Text] [Related]
9. Epitope base editing: Non-malignant stem cells are going undercover.
Saniei S; Wagenblast E
Cell Stem Cell; 2023 Nov; 30(11):1400-1402. PubMed ID: 37922877
[TBL] [Abstract][Full Text] [Related]
10. A proposed predictive mathematical model for efficient T-cell collection by leukapheresis for manufacturing chimeric antigen receptor T cells.
Huang X; Gan GPL; Chan EHL; Heng KK; Perumal S; Salleh R; Teo JML; Xie G; Lee JJ; Ho AYL; Hwang WYK; Linn YC; Chen Y; Quek JKS; Than H; Nagarajan C; Lim FLWI
Haematologica; 2023 Nov; 108(11):3131-3134. PubMed ID: 37165850
[No Abstract] [Full Text] [Related]
11. Clonal myeloid disorders following CAR T-cell therapy.
Andersen M; Bindal P; Michaels P; Elavalakanar P; Liegel J; Dias A; Arnason J; Patell R
Ann Hematol; 2023 Dec; 102(12):3643-3645. PubMed ID: 37749320
[No Abstract] [Full Text] [Related]
12. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
[TBL] [Abstract][Full Text] [Related]
14. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Svoboda J; Rheingold SR; Gill SI; Grupp SA; Lacey SF; Kulikovskaya I; Suhoski MM; Melenhorst JJ; Loudon B; Mato AR; Nasta SD; Landsburg DJ; Youngman MR; Levine BL; Porter DL; June CH; Schuster SJ
Blood; 2018 Sep; 132(10):1022-1026. PubMed ID: 29925499
[TBL] [Abstract][Full Text] [Related]
15. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.
Rossi J; Paczkowski P; Shen YW; Morse K; Flynn B; Kaiser A; Ng C; Gallatin K; Cain T; Fan R; Mackay S; Heath JR; Rosenberg SA; Kochenderfer JN; Zhou J; Bot A
Blood; 2018 Aug; 132(8):804-814. PubMed ID: 29895668
[TBL] [Abstract][Full Text] [Related]
16. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
[TBL] [Abstract][Full Text] [Related]
18. CAR T cells find strength in polyfunction.
Davila ML
Blood; 2018 Aug; 132(8):769-770. PubMed ID: 30139827
[No Abstract] [Full Text] [Related]
19. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
20. T Cells Expressing NKG2D CAR with a DAP12 Signaling Domain Stimulate Lower Cytokine Production While Effective in Tumor Eradication.
Ng YY; Tay JCK; Li Z; Wang J; Zhu J; Wang S
Mol Ther; 2021 Jan; 29(1):75-85. PubMed ID: 32956627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
